UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead
Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.
Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."
Edwards Lifescience closed at $104.44 on Thursday.
Latest Ratings for EW
|Feb 2017||BTIG Research||Downgrades||Buy||Neutral|
|Dec 2016||Cowen & Co.||Maintains||Outperform||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.